Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
COCP•Phase 1b human challenge study update
Sept. 9 (Reuters) - Cocrystal Pharma Inc COCP.O:
- Cocrystal Pharma announces last subject dosed in Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment.
- Preliminary efficacy results for CDI-988 are expected late 2026 or early 2027.
- No serious adverse events have been reported to date in the CDI-988 Phase 1b study.
